2024 International Congress » Parkinson’s Disease: Clinical Trials

24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease

S. Thirunavukarasu, B. Ramanan, V. Varadharaj, TS. Suresh, KV. Verma, HAJ. Janardhanan, AUR. Ur (PUDUCHERRY, India)

A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment

N. Shanbhag, J. Padmanabhan, Z. Zhang, B. Harel, H. Jia, T. Kangarloo, W. Yin, A. Dowling, A. Laurenza, P. Khudyakov, K. Galinksy, R. Latzman, T. Simuni, D. Weintraub, F. Horak, C. Lustig, P. Maruff, A. Simen (Cambridge, USA)

A Pilot Study of Intrajejunal Faecal Microbiota Transplant to Improve Motor Function in Patients with Parkinson’s Disease Treated with Levodopa-carbidopa Intestinal Gel: Preliminary Findings.

D. Wilson, L. Williams, S. Waller, S. Dal, J. Qiu, D. Tsui, S. Bray, J. Griffith, D. Galea, X. Chen, F. Tudehope, L. Bracken, H. Morales-Briceno, N. Mahant, F. Chang, S. Bandodkar, D. Van-Der-Poorten, V. Fung (Sydney, Australia)

A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson’s Disease

M. Soileau, M. Bouchard, I. Malaty, J. Parra, L. Bergmann, R. Gupta, A. Spiegel, E. Freire-Alvarez (Georgetown, USA)

A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson’s Disease (eCAP-PD): Technical and Design Considerations

L. Verhagen, T. Virmani, M. Pourfar, C. Hess, J. Rosenow, E. Petersen, A. Mogilner, J. Karl, N. Shetty (Chicago, USA)

A Randomized, Double-Blind, Placebo-Controlled Trial of a Multi-Strain Probiotic for Anxiety in Parkinson’s Disease

J. Lam, P. Uzelman, J. Zhu, D. Meng, F. Pio, S. Appel-Cresswell (Vancouver, Canada)

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, G. Respondek, A. Monnet, N. Shariati, L. Rutten-Jacobs, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (Basel, Switzerland)

AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions

Y-H. Chang, M. Periñan, A. Noyce (London, United Kingdom)

Adaptive vs Conventional Chronic Deep Brain Stimulation: Results from a Randomized Pilot Trial in Parkinson’s Disease

I. Isaias, S. Marceglia, L. Romito, R. Eleopra, L. Borellini, V. Levi, M. Locatelli, T. Mandat, E. Pirola, A. Ampollini, M. Lanotte, L. Lopiano, M. Zibetti, A. Bentivoglio, C. Piano, A. Izzo, F. Tamma, G. Foffani, A. Lozano, E. Moro, J. Volkmann, C. Conti, M. Arlotti, L. Krinke, L. Rossi, A. Priori (Milan, Italy)

Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium

D. Stephenson, C. Kopil, M. Müller, O. Mabrouk, H. Kocherla, R. Comley, K. Yee, T. Dam, G. Pagano, J. Seibyl, K. Marek, T. Simuni (Tucson, USA)

AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease

SB. Soumma, D. Peterson, H. Ghasemzadeh, S. Mehta (Tempe, USA)

Analgesic effect of electroacupuncture on Relieving pain in Parkinson’s disease and the mechanism based on rs-fMRI

JUN. Li (Hefei, China)

Analysis of Patellar Reflex in Parkinson Disease Patients after an Acupuncture Treatment Protocol – Case Series Study

CRP. Pereira (Porto, Portugal)

Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention

B. Mcmahon, L. Lemon, R. Dobkin, E. Brown, J. Dimos, M. Kuhl, L. Heathers (Baltimore, USA)

Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study

BP. Bridges (St. John's, Canada)

Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson’s Disease Patients

R. Dias, M. Piemonte, G. Gomes, L. Bitaraes (Sao Paulo, Brazil)

Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins

C. Murray, C. Kusiak, A. Vanderbeek, D. Bertolini, E. Tramel (San Francisco, USA)

Centralizing brain tissue donation for a large multi-site Parkinson’s disease (PD) study

L. Heathers, T. Foroud, G. Antonopoulos, K. Mantravadi, B. Lenfert (Indianapolis, USA)

Cervical percutaneous interferential current stimulation improves cough reflex and oral residue in patients with Parkinson’s disease

M. Nakamori, M. Toko, H. Yamada, Y. Hayashi, K. Yoshikawa, A. Hiraoka, M. Yoshikawa, T. Nagasaki, Y. Mikami, H. Maruyama (Hiroshima, Japan)

Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy

B. Bicknell, G. Herkes, A. Liebert, H. Kiat (, Westmead, Australia)

Characterisation of the Pattern of Daily Motor Fluctuations in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612

W. Poewe, A. Ellenbogen, N. Lopes, R. Pahwa (Innsbruck, Austria)

Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism

C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, T. Hue, C. Schambach, D. Kreisel, D. Young, I. Bledsoe, L. Racelo, P. Nanda Kumar, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, J. Falcon, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings (SAN FRANCISCO, USA)

Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Real-World, USA Experience

M. Okun, K. Foote, T. Zesiewicz, Y. Bezchlibnyk, A. Papanastassiou, O. Vaou, J. Carlson, J. Aldred, V. Krishna, C. Luca, J. Jagid, J. Durphy, L. Verhagen Metman, S. Sani, S. Ojemann, D. Kern, D. Weintraub, R. Ramdhani, A. Siadati, B. Sundaram, C. Zhao, D. Martinez, M. Siddiqui, S. Tatter, L. Chen, E. Goldberg (Gainesville, USA)

Common and specific immediate effects in brain oscillations and motor symptoms of tDCS and tACS in Parkinson’s disease: A randomized controlled trial

JJ. Bu, JF. Liu, H. Wan, C. Jin (Hefei, China)

Comparing digital gait and turning measures from a prescribed gait test in the clinic/laboratory versus the same test at home in people with Parkinson’s disease

V. Shah, C. Silva-Batista, P. Burgos, A. Ragothaman, P. Carlson-Kuhta, K. Sowalsky, F. Horak, M. Mancini (Portland, USA)

Comparing Ring and Directional Globus Pallidus Stimulation Effects on Parkinson’s Gait

A. Ragothaman, Z. Nhem, G. Harker, P. Carlson-Kuhta, L. Neilson, C. Zarns, M. Case, A. Becker, R. Raike, K. Burchiel, M. Mancini, D. Safarpour (Portland, USA)

Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants

P. Agarwal, A. Formella, N. Crouse, A. Breiteneicher, M. Grall (Kirkland, USA)

Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study

P. Lewitt, S. Isaacson, A. Espay, S. Reyes, A. Formella, G. Ceresoli-Borroni (Detroit, USA)

Coordinated Reset Vibrotactile Therapy for the Treatment of Bradykinesia in Parkinson’s Disease Patients

P. Luu, E. Kabasenche, M. Gutierrez, M. Fisher, B. Gaston, R. Shusterman, K. Morgan, D. Tucker (Eugene, USA)

Correlation Between Sleep and Quality of Life in People With Parkinson’s Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa

I. Malaty, O. Vaou, R. Hauser, B. Bergmans, P. Odin, M. Shah, L. Bergmann, L. Harmer, R. Gupta, K. Chaudhuri (Gainesville, USA)

Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial

R. Ellis-Doyle, ML. Zeissler, C. Gonzalez-Robles, M. Bartlett, S. Collins, S. Del-Din, S. Haar, M. Hu, A. Jha, C. Lambert, A. Noyce, R. Petty, K. Pushparatnam, L. Rochester, C. Siu, G. Mills, A. Schrag, T. Foltynie, C. Carroll, A. Yarnall (London, United Kingdom)

Differential Symptom Cluster Responses and Predictors to Repetitive Transcranial Magnetic Stimulation Treatment in Parkinson’s Disease：A Retrospective Study

J. Sun, P. Hu (hefei, China)

Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial

M. Ansari, Y. Yang, S. Elliott, M. Naganawa, P. Honhar, M. Dias, S. Henry, J. Ropchan, R. Comley, N. Nabulsi, Y. Huang, R. Carson, S. Finnema, S. Nikayin, S. Tinaz, D. Matuskey, G. Sanacora, S. Holmes (New Haven, USA)

Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612

S. Isaacson, O. Rascol, H. Sarva, R. Hauser, F. Stocchi, N. Lopes, L. Salin, J. Pereira, N. Giladi (Boca Raton, USA)

Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study

H. Nagayama, T. Hatano, R. Sengoku, N. Yanagisawa, O. Kano (Tokyo, Japan)

Effect of Levodopa therapy in Hypokinetic Dysarthria in Parkinson’s Disease

E. Smaoui, N. Farhat, S. Daoud, K. Moalla, N. Bouattour, M. Damak, C. Mhiri (Sfax, Tunisia)

Effect of Opicapone and Levodopa on Daily Motor Patterns in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

Effect of Opicapone and Levodopa on the Different Daily OFF Patterns in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial

G. Pagano, A. Monnet, A. Reyes, B. Ribba, H. Svoboda, T. Kustermann, T. Simuni, R. Postuma, N. Pavese, F. Stocchi, K. Brockmann, K. Smigorski, V. Gerbaldo, P. Fontoura, R. Doody, G. Kerchner, P. Brundin, K. Marek, A. Bonni, T. Nikolcheva (Basel, Switzerland)

Effects of Mental Practice on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial

P. Silva, K. Honda, I. Nascimento, K. Nobrega, N. Pereira, T. Barolli (Sao Paulo, Brazil)

Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support

M. Soileau, J. Bronstein, L. Harmer, M. Shah, R. Gupta, L. Verhagen Metman (Georgetown, USA)

Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of PD and Experiences of Daily Living

O. Rascol, S. Isaacson, P. Lewitt, W. Poewe, J. Ferreira, N. Lopes, S. Sopromadze, J. Pereira, C. Olanow (Toulouse, France)

Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease

A. Videnovic, E. Macklin, C. Coffey, M. Cudkowicz, HJ. Cho, J. Ohayon, A. Amara, K. Marder, P. Zee, C. Desir, H. Ernst, E. Steinhart, M. Costigan, A. Gudjonsdottir, D. Ecklund, M. Chase, S. Criswel, D. Charles, J. Coleman, A. Espay, A. Hung, S. Kadimi, A. Killoran, L. Luo, R. Malkani, J. Margolesky, J. Marsella, C. Maurer, D. Mihaila, P. Moretti, A. Park, P. Phielipp, H. Sarva, B. Shah, H. Shill, A. Siderowf, V. Suski, J. Tate, W. Tse, K. Wyant, L. Zhang, E. Klerman (Boston, USA)

Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12-Week, Randomized Study

S. Isaacson, R. Kirsner, O. Vaou, R. Pahwa, R. Hauser, L. Bergmann, R. Gupta, M. Shah, S. Varughese, T. Kimber (Boca Raton, USA)

Experiences of a personalised intervention to support self-management in PwP – PD-Care: Live Well with Parkinson’s

T. Rookes, K. Kantilal, K. Walters, N. Kime, A. Kassavou, M. Younossi, WN. Tsang, P. Schartau, B. Gardner, N. Davies, A. Schrag (London, United Kingdom)

Exploring feasibility and efficacy of a ballet-based intervention in advanced Parkinson’s disease.

A. Podlewska, L. Batzu, V. Leta, J. Staunton, P. Tall, M. Recaman, A. Rizos, F. Derbyshire-Fox, A. Hartley, I. Bakolis, C. Pariante, T. Woods, K. Ray Chaudhuri (London, United Kingdom)

Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study

S. Putri, R. Fajar, E. Syafruddin (Gresik, Indonesia)

First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease

T. Lewis, B. Calamini, L. Verselis, M. Lowrey, L. Shaughnessy, J. Deranick, M. Dieter, M. Krautkramer, O. Uspenskaya, J. Sevigny (New York, USA)

Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)

B. Bicknell, S. Tilley, G. Herkes, A. Liebert (, Westmead, Australia)

Gait Digital Outcomes Exploration from Continuous Real-World Recordings in Parkinson’s Disease

M. Michaud, G. Parinello, E. Kluczka, C. Cluzeau, M-L. Brechemier, F. Bompaire, C. Tafani, M. Sallansonnet-Froment, T. Gidaro, L. Oudre, D. Ricard (Gif-Sur-Yvette, France)

Gathering Prodromal Participant Perspective on Receiving Personal Research Information

C. Destro, M. Mcguire Kuhl, J. Schulze, L. Heathers, T. Foroud, T. Tropea, B. Henry, J. Talarico, C. Stanley, E. Flagg (New York, USA)

GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation

O. Siemeling, S. Slingerland, S. V/d Zee, T. van Laar (Groningen, Netherlands)

Identifying Subjects with Dopamine Transporter Deficit in a Population-based Recruitment Strategy: Kassel Data of Healthy Brain Ageing

S. Schade, K. Rege, C. Corinne, A. Garrido, T. Marques, P. Mahlknecht, S. Ghosh, R. Rawal, C. Pauly, T. Wicke, E. Lang, S. Schnell, S. Scaglione, H. Hakelberg, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer, D. Pilco (Kassel, Germany)

Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day

A. Ellenbogen, J. Ferreira, F. Stocchi, K. Kieburtz, A. Albanese, L. Adar, N. Vostokova, J. Pereira, R. Hauser (Farmington Hills, USA)

Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

S. Isaacson, H. Fernandez, C. Kilbane, G. Banisadr, A. Pitman, S. Fisher, R. D'Souza (Boca Raton, USA)

Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention.

L. Lemon, A. Faraday, J. Nevins, M. Nygard, M. Mcmahon (Cincinnati, USA)

Inter- and intra-day variability in β-Glucocerebrosidase activity and pathway biomarkers in healthy volunteers and patients with Parkinson’s disease with a GBA1 mutation

J. Vandervalk, D. Dumas, E. Thijssen, D. Pereira, W. Grievink, Y. Yavuz, C. Pesch, D. Ysselstein, M. Hagey, J. Cedarbaum, K. Hunt, P. Kremer (Leiden, Netherlands)

Interim Analysis of the Feasibility of Mediterranean-Ketogenic Dietary Interventions in Parkinson’s Disease

K. Tosefsky, Y. Wang, A. Kuan, V. Ngo, C. Agu, D. Liang, L. Liu, O. Geiger, S. Keymanesh, M. Sacheli, E. Gerson, S. Cresswell (Vancouver, Canada)

Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative

M-L. Zeissler, N. Lapelle, S. Collins, E. Cowd, C. Gonzalez-Robles, R. Ellis-Doyle, G. Mills, R. Petty, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)

Intrinsic Auricular Muscle Zone Stimulation for Moderate-to-Severe Parkinson’s Disease

S. Brillman, A. Samiian, V. Sharma, S. Ertan, . öztop çakmak (Palo Alto, USA)

Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease

G. Ozay, I. Zhang, M. Umali, L. Lovelace, M. Barry, L. Ariza Serrano, A. Sharma, L. Raslan, Y. Torres-Yaghi, F. Pagan (Washington, USA)

Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

T. Guttuso, JR., R. Shepherd (Williamsville, USA)

Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson’s Disease

A. Espay, R. Pahwa, A. Ellenbogen, F. Stocchi, N. Giladi, L. Salin, N. Sasson, J. Pereira, O. Rascol (Cincinnati, USA)

Long-term evaluation of advanced Parkinson’s disease burden and clinical outcomes: results from the PROSPECT observational study

A. Espay, H. Watanabe, A. Lehn, F. Ory-Magne, T. Mestre, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, P. Alonso (Cincinnati, USA)

Long-Term Evolution of Advanced Parkinson’s Disease Burden: Subgroup Analysis from the 24 Month International PROSPECT Observational Study

O. de Fabregues, D. Falconer, S. Heshmat, D. Houghton, D. Maltete, Y. Mukai, M. Rollins, L. Bergmann, P. Kukreja, K. Onuk, J. Sarna (Barcelona, Spain)

Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension

F. Bergquist, J. Aldred, C. Carroll, E. Danielsen, M. Facheris, R. Gupta, A. Jeong, A. Spiegel, V. Fung (Mölndal, Sweden)

Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)

LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics

D. Jennings, S. Huntwork-Rodriguez, J. Kluss, S. Ota, S. Dhuria, R. Maciuca, K. Fraser, B. Hersh, Z. Berger, C. Ho, P. Chin (South San Francisco, USA)

Lumbar Punctures in Parkinson’s Research

A. Navangul, H. Matthews, M. Bartlett, H. Groves, S. Stott, A. Noyce (London, United Kingdom)

Machine Learning Model Comparison for Freezing of Gait Prediction in Advanced Parkinson’s Disease Patients

J. Watts, A. Khojandi, R. Ramdhani (Knoxville, USA)

Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson’s Disease

F. Hansson, S. Waters, N. Waters, J. Tedroff (Gothenburg, Sweden)

Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease

K. Rosqvist, P. Odin (Lund, Sweden)

Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study

MF. Valero García, E. Bargay Pizarro, I. Legarda Ramirez, B. Vives Pastor, L. Núñez Santos, S. Jesus Maestre, M. Cosgaya, J. Garcia Caldentey, N. Caballol, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, C. Borrué, B. Solano Vila, M. álvarez Saúco, L. Vela, S. Escalante, E. Cubo, JC. Martínez Castrillo, P. Sánchez Alonso, MG. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Seijo Martinez, C. Ordás, P. Martinez-Martin, P. Mir, D. Santos-García (Palma de Mallorca, Spain)

Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias

H. Salhi, D. Maltête, S. Thobois, G. Fenelon, F. Ory, L. Defevre, G. Mangone, G. Defer, AR. Marques, S. Frismand, S. Drapier, JP. Azulay, C. Geny, G. Dupont, A. Doe-de-Maindreville, C. Barberot, D. Devos, JC. Corvol, O. Rascol, E. Audureau, P. Remy (Creteil, France)

Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.

C A. Hurtado-Gonzalez, J F. Ayala-Rico, S. Ospina-Otalvaro, P A. Lenis, J M. Márquez, C O. Moreno, M. Agudelo, S. Guerrero (Cali, Colombia)

Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study

T. Gurevich, S. O'Sullivan, J. Parra, M. O'Meara, J. Zamudio, A. Fasano (Tel Aviv-Yafo, Israel)

Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease

M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Wuhan, China)

Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON

J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, G. Castilla-Fernández, J. Rocha, J. Holenz, W. Poewe (Lisbon, Portugal)

Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease

J. Ferreira, J. Lee, H. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonesca, J. Rocha, G. Castilla-Fernández, J. Holenz, O. Rascol (Lisbon, Portugal)

Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial

J. Ferreira, M. Gago, R. Costa, M. Fonesca, J. Almeida, J. Rocha, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

Orthostatic hypotension in age-related neurodegenerative diseases: a bibliometric study from 2007 to 2023

Y. Qu, B. Zhang, C. Xing, Y. Yuan (Xi'an, China)

Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

Parkinson Patients` Motor and Cognitive Functions are Improved by High Intensity LSVT®BIG Physiotherapy – a Randomized Prospective Pilot Trial

B. Wimmer, B. Budeus, M. Katzer, C. Preiner, T. Wächter, K. Seppi, U. Bogdahn (Innsbruck, Austria)

Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression

B. Mcmahon, A. Siderowf, T. Simuni, C. Tanner, B. Mollenhauer, C. Coffey, D. Galasko, K. Poston, L. Chahine, R. Dobkin, T. Foroud, K. Kieburtz, D. Weintraub, K. Merchant, M. Frasier, T. Sherer, S. Chowdury, E. Brown, R. Alcalay, A. Videnovic, K. Fabrizio, E. Flagg, C. Stanley, K. Marek (Baltimore, USA)

Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants

P. Agarwal, N. Crouse, A. Breiteneicher, M. Formella (Kirkland, USA)

PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson’s Disease through objective measurements and patient reported outcomes – a multicenter randomized controlled trial.

N. Karottki, T. Hørmann Thomsen, P. Jennum, M. Blaabjerg, B. Biering-Sørensen (Glostrup, Denmark)

Personality may influence the response to apomorphine infusion in Parkinson’s disease patients

M. Boussac, E. Harroch, C. Barthelemy, F. Ory-Magne, C. Leung, M. Fabbri, C. Arbus, C. Brefel-Courbon (Toulouse, France)

Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease

C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, J. Labreuche, A. Duhamel, C. Barthelemy, D. Lannoy, N. Carta, B. Palas, F. Marchand, B. Gouges, C. Leclerc, C. Potey, T. Ouk, K. Dujardin, S. Baigne, L. Carton, AS. Rolland, JC. Devedjian, V. Foutel, D. Deplanque, M. Fisichella, D. Devos (Lille, France)

Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

W. Cubała, A. Berrio, K. Chi-Burris, G. Alva, L. Chrones, S. Pathak (Gdańsk, Poland)

Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease

R. Hauser, M. Bouchard, D. Santos-Garcia, L. Bergmann, R. Gupta, L. Harmer, M. Shah, C. Yan, S. Isaacson (Tampa, USA)

Preliminary Efficacy of Bilateral Intraputaminal Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 18-Month Follow-Up From a Phase 1b Study

N. Phielipp, C. Christine, A. Merola, J. Elder, P. Larson, W. San Sebastian, M. Fiandaca, C. Urrea, M. Wisniewski, A. van Laar, A. Kells, K. Bankiewicz (Irvine, USA)

Programming Adaptive Deep Brain Stimulation in the Clinic: Lessons from the ADAPT-PD Trial

T. Herrington, M. Beudel, J. Ostrem, S. Little, L. Almeida, A. Ramirez-Zamora, A. Fasano, T. Hassell, K. Mitchell, E. Moro, M. Gostkowski, N. Sarangmat, S. Stanslaski, L. Tonder, Y. Tan, R. Summers, T. Goble, R. Raike, H. Bronte-Stewart (Boston, USA)

Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): PDQ-39 Results from a Phase 3 Randomized Active-Controlled Study

H. Sarva, M. Tagliati, W. Poewe, F. Stocchi, O. Rascol, T. Yardeni, N. Lopes, J. Pereira, A. Espay (New York, USA)

Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial

E. Mitchell (London, United Kingdom)

Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease.

NES. Chtioui, CHR. Duval, DAV. St-Pierre (Montreal, Canada)

REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease

A. Whone, C. Christine, M. Luz, R. Richardson, C. Urrea, N. Chhabria, C. Letourneau, M. Wisniewski, M. Fiandaca, A. van Laar, A. Kells, K. Bankiewicz (Bristol, United Kingdom)

Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease

E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Marshall, M. Korell, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease

K. Waddell, M. Smith, S. Wood, R. Greysen, J. Morley (Philadelphia, USA)

Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process

T. Tropea, J. Schulze, C. Destro, L. Heathers, B. Henry, JM. Talarico, C. Stanley, M. Mcguire Kuhl, E. Flagg, T. Foroud (Philadelphia, USA)

Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies

R. Petty, V. Agarwal, J. Allison, S. Bartolomeu Pires, M. Bartlett, T. Boey, R. Croucher, H. Collins, S. Collins, E. Davies, J. Duffen, R. Ellis-Doyle, C. Gonzalez-Robles, F. Hudson, J. Inches, L. Miller, G. Mills, S. Wonnacott, T. Foltynie, C. Carroll, S. Mullin, M. Zeissler (Plymouth, United Kingdom)

Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience

C. Gonzalez-Robles, S. Al-Bachari, M. Bartlett, R. Petty, S. Collins, R. Ellis-Doyle, G. Mills, P. Piccini, K. Pushparatnam, C. Siu, Z. Walker, M-L. Zeissler, C. Carroll, T. Foltynie, R. Weil, A. Schrag, C. Lambert (London, United Kingdom)

Sleep disorders in Parkinson’s disease

M. Mirqosimova (Dushanbe, Tajikistan)

Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention

T. Oosterhof, E. Mitchell, A. Ascherio, B. Bloem, K. van Dijk, B. Dijkstra, L. Kaufmann, R. Lathey, E. Macklin, A. Navangul, A. Pijpers, H. Rowbotham, R. Schneider, M. Schwarzschild, N. de Vries, A. Noyce, S. Darweesh (Nijmegen, Netherlands)

Split-belt Treadmill Training to Rehabilitate Freezing of Gait and Balance in Parkinson’s Disease

S. Sasikumar, A. Fasano, G. Sorrento (Toronto, Canada)

Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson’s Patients

W. Poewe, A. Espay, N. Lopes, J. Ferreira (Innsbruck, Austria)

The 201 Trial in Untreated Parkinson’s Disease

M. Werner, CW. Olanow, A. Mcgarry, C. Meyer, E. Mancino, C. Klint, J. Pellecchia (Atlanta, USA)

The Effect of Stochastic Resonance Stimulation in Neural Control of Balance During Walking in Parkinson Disease

E. Alsaqabi, S. Dibianca, A. Sansare, K. Verma, J. Jeka, H. Reimann (Newark, USA)

The Effect of Subjective Postural Vertical on Forward Flexed Posture in Parkinson’s disease

M. Shiraishi, K. Mikami, H. Kamo, Y. Okuma, T. Tsunemi, K. Fujimoto, T. Kamo, Y. Yokota, S. Nogawa, T. Osada, M. Seki, H. Nagayama, T. Hatano, H. Nakajima, K. Suzuki, T. Yamamoto, Y. Yamano, N. Hattori, M. Ijima (Kawasaki City, Japan)

The Effects of Baduanjin on Fine Motor Skills in Mild and Moderate Parkinson’s Disease

JUN. Li, KF. Li, HZ. Chen, WM. Yang (Hefei, China)

The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial

C. Han, Y. Xia, J. Wu, Y. Sun, L. Kou, J. Huang, Q. Wang, E. Xu, H. Yu, Q. Ye, X. Luo, H. Ma, H. Chen, L. Wang, T. Wang (wuhan, China)

The HIIT-Home4Parkinson’s study

C. Harpham, L. Connolly, H. Gunn, J. Marsden (Plymouth, United Kingdom)

The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)

J. Cedarbaum, B. Koo, L. Zhang, K. Mead, S. Patel, V. Reddy, D. Hafler (New Haven, USA)

The relationship between pain threshold and striatal dopamine function in Parkinson’s Disease

H. Kawasaki, Y. Sakasai, S. Fujita, R. Yokoyama, K. Seo, Y. Ito, T. Yamamoto (moroyama, Japan)

Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial

J. O'Sullivan, N. Jayabalan, N. Birch, D. Mondhe, A. Lehn, R. Gordon, R. Adan (Brisbane, Australia)

Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease

J. Aldred, T. Henriksen, M. Bouchard, J. Martínez-Castrillo, M. Soileau, D. Standaert, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (Spokane, USA)

Unraveling Plantar Pressure Dynamics in Parkinson’s Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors

T. Tiraweerakhajorn, W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

WATCH-PD Qualitative Study: A Mental Model of Coping with Disease Progression

A. Lerner, J. Mammen, R. Al-Rubayie, M. Kostrzebski, J. Adams (Rochester, USA)

WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update

J. Adams, A. Lerner, R. Al-Rubayie, T. Kangarloo, Y. Gong, V. Khachadourian, B. Tracey, D. Volfson, R. Lazman, J. Cosman, J. Edgerton, D. Anderson, A. Best, M. Kostrzebski, P. Auinger, C. Tarolli, M. Müller, D. Stephenson, E. Dorsey (Rochester, USA)